Clovis Oncology Inc (NASDAQ:CLVS) announced that the U.S.
In a research report released Tuesday, Chardan Capital analyst Madhu Kumar initiated coverage on shares of Clovis Oncology Inc (NASDAQ:CLVS) with a Sell rating and …
Clovis Oncology Inc (NASDAQ:CLVS) shares are under pressure today after the biotech firm presented additional detailed efficacy and safety data from the NDA dataset of …
Clovis Oncology Inc (NASDAQ:CLVS) investors are heading for the hills after the cancer drug maker announced the oral presentation of the primary efficacy and safety …
We await full ruca data at ESMO to better define rucaparib’s profile, says Piper Jaffray
Clovis Oncology Inc (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2016, and provided an update on the Company’s clinical development programs …
Clovis Oncology Inc (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as …
Healthcare analysts commented on Clovis Oncology Inc (NASDAQ:CLVS) and Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) following an FDA Committee decision and an FDA Fast Track designation, respectively.
Shares of Clovis Oncology Inc (NASDAQ:CLVS) tumbled nearly 5% today, after the FDA’s Oncologic Drugs Advisory Committee (ODAC) panel voted 12-1 to wait for Clovis’ randomized …
